CLB
Neutral signalScored 2026-08-05 Drivers: Congress, fundamentals. Moteurs : Congrès, fondamentaux.
Research, not advice.
À propos
Core Laboratories N.V.
- Nom
- Core Laboratories N.V.
- Secteur
- Energy
- Industrie
- Oil & Gas Equipment & Services
- Bourse
- NYSE
- Capitalisation
- $451.0M
- Employés
- 3,300
- PDG
- Lawrence V. Bruno
- Site web
- https://www.corelab.com
- Marché
- BORRCAPLGRNTHPKNBRPDS
Core Laboratories N.V. (CLB) is a global provider to the oil and gas sector, delivering specialized services and products for characterizing subterranean reservoirs and optimizing hydrocarbon extraction. The company's operations are distinctly segmented into Reservoir Description and Production Enhancement. The Reservoir Description division meticulously analyzes petroleum reservoir rock, fluid, and gas samples. This detailed scientific examination aims to boost the yield and enhance the recovery of oil and gas from clients' reservoirs. Offerings in this segment encompass comprehensive laboratory analysis and on-site field evaluations to determine the properties of crude oil and refined products, alongside performing proprietary and collaborative industry research studies. Conversely, the Production Enhancement segment furnishes an array of services and products vital for well completions, perforations, stimulation processes, and general production activities. This includes providing integrated diagnostic tools designed to assess the efficacy of well completions and to devise strategies for more effective enhanced oil recovery initiatives. Core Laboratories markets and sells its solutions through diverse channels, including direct sales representatives, educational seminars, industry trade exhibitions, print advertising, and a network of distributors. Established in 1936, the company boasts a significant international presence, conducting operations in approximately 50 countries, with its corporate headquarters situated in Amstelveen, the Netherlands.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 5 000 titres (~53 900,00 $ US)
- Insiders
- Bruno Lawrence
- Total bought
-
$53,900
Avg buy (VWAP, 90d window) $10.78 vs last close —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-07-31
- Last synced
-
2026-10-20 00:36:23
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-07-31 | Bruno Lawrence | Buy · P | 5,000 | $10.78 | $53,900 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2018-12-10 | Thomas J. Rooney | Sale (Full) | $15,001 - $50,000 |
| 2018-10-24 | Thomas Charles MacArthur | Sale (Partial) | $1,001 - $15,000 |
| 2018-10-23 | Thomas Charles MacArthur | Sale (Partial) | $1,001 - $15,000 |
| 2018-06-07 | Thomas Charles MacArthur | Purchase | $15,001 - $50,000 |
Signal
Neutral signalScored 2026-08-05 Drivers: Congress, fundamentals. Moteurs : Congrès, fondamentaux.
CLB shows adequate liquidity (75) and moderate fundamental stability, but stagnant top-line growth, shrinking headcount, and zero R&D investment structurally cap upside potential.
The first sentence of the analysis written for CLB on 2026-08-05 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. 1 purchase disclosure year to date, a thin reading
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 2.02 · operating margin 9.6%
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 17.9% | 16.9% | 18.4% | 16.1% | 17.8% | |
| Ebit Margin | 10.7% | 11.2% | 10.7% | 8.5% | 9.6% | |
| Ebitda Margin | 13.5% | 14.0% | 13.8% | 12.0% | 13.6% | |
| Operating Profit Margin | 9.6% | 11.2% | 10.7% | 8.5% | 9.6% | |
| Pretax Profit Margin | 8.7% | 8.8% | 8.1% | 6.1% | 7.7% | |
| Continuous Operations Profit Margin | 5.8% | 6.1% | 7.3% | 4.0% | 4.3% | |
| Net Profit Margin | 5.6% | 6.0% | 7.2% | 4.0% | 4.2% | |
| Bottom Line Profit Margin | 5.6% | 6.0% | 7.2% | 4.0% | 4.2% | |
| Current Ratio | 2.025 | 2.322 | 2.533 | 2.053 | 2.083 | |
| Quick Ratio | 1.511 | 1.713 | 1.719 | 1.467 | 1.582 | |
| Solvency Ratio | 0.142 | 0.139 | 0.147 | 0.094 | 0.091 | |
| Cash Ratio | 0.214 | 0.196 | 0.172 | 0.150 | 0.195 | |
| Price To Earnings Ratio | 23.574 | 25.836 | 22.354 | 48.262 | 51.884 | |
| Price To Earnings Growth Ratio | 15.794 | -1.701 | 0.254 | -20.753 | -0.433 | |
| Forward Price To Earnings Growth Ratio | 15.794 | -1.701 | 0.254 | -20.753 | -0.433 | |
| Price To Earnings Diluted Ratio | 23.574 | 26.227 | 22.935 | 48.262 | 53.119 | |
| Price To Earnings Diluted Growth Ratio | 7.779 | -1.836 | 0.275 | 0.000 | -0.445 | |
| Price To Book Ratio | 2.802 | 3.221 | 3.667 | 5.097 | 6.561 | |
| Price To Sales Ratio | 1.416 | 1.550 | 1.617 | 1.918 | 2.183 | |
| Price To Free Cash Flow Ratio | 33.438 | 18.722 | 58.017 | 63.717 | 44.551 | |
| Price To Operating Cash Flow Ratio | 20.129 | 14.396 | 33.258 | 37.634 | 28.061 | |
| Debt To Assets Ratio | 0.281 | 0.305 | 0.367 | 0.385 | 0.431 | |
| Debt To Equity Ratio | 0.617 | 0.715 | 0.958 | 1.207 | 1.600 | |
| Debt To Capital Ratio | 0.381 | 0.417 | 0.489 | 0.547 | 0.615 | |
| Long Term Debt To Capital Ratio | 0.293 | 0.334 | 0.421 | 0.483 | 0.547 | |
| Financial Leverage Ratio | 2.196 | 2.343 | 2.608 | 3.139 | 3.713 | |
| Working Capital Turnover Ratio | 4.431 | 3.968 | 4.185 | 4.735 | 5.394 | |
| Operating Cash Flow Ratio | 0.349 | 0.578 | 0.281 | 0.242 | 0.403 | |
| Operating Cash Flow Sales Ratio | 0.070 | 0.108 | 0.049 | 0.051 | 0.078 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.602 | 0.769 | 0.573 | 0.591 | 0.630 | |
| Debt Service Coverage Ratio | 5.260 | 4.808 | 4.932 | 4.182 | 5.232 | |
| Interest Coverage Ratio | 4.776 | 4.734 | 4.069 | 3.589 | 4.946 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 0.226 | 0.313 | 0.115 | 0.112 | 0.146 | |
| Capital Expenditure Coverage Ratio | 2.512 | 4.328 | 2.343 | 2.443 | 2.702 | |
| Dividend Paid And Capex Coverage Ratio | 2.230 | 3.783 | 1.992 | 2.068 | 2.379 | |
| Dividend Payout Ratio | 0.063 | 0.060 | 0.051 | 0.095 | 0.093 | |
| Enterprise Value Multiple | 12.468 | 13.233 | 14.550 | 19.531 | 19.741 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 17.9% | ▲1.0% | ▲0.5% |
| Ebit Margin | 10.7% | ▼-0.4% | ▲0.6% |
| Ebitda Margin | 13.5% | ▼-0.5% | ▲0.1% |
| Operating Profit Margin | 9.6% | ▼-1.6% | ▼-0.3% |
| Pretax Profit Margin | 8.7% | ▼-0.1% | ▲0.8% |
| Continuous Operations Profit Margin | 5.8% | ▼-0.4% | ▲0.3% |
| Net Profit Margin | 5.6% | ▼-0.4% | ▲0.2% |
| Bottom Line Profit Margin | 5.6% | ▼-0.4% | ▲0.2% |
| Current Ratio | 2.025 | ▼-0.297 | ▼-0.178 |
| Quick Ratio | 1.511 | ▼-0.203 | ▼-0.087 |
| Solvency Ratio | 0.142 | ▲0.003 | ▲0.019 |
| Cash Ratio | 0.214 | ▲0.018 | ▲0.029 |
| Price To Earnings Ratio | 23.573 | ▼-2.262 | ▼-10.808 |
| Price To Earnings Growth Ratio | 15.794 | ▲17.495 | ▲17.162 |
| Forward Price To Earnings Growth Ratio | 15.794 | ▲17.495 | ▲17.162 |
| Price To Earnings Diluted Ratio | 23.573 | ▼-2.654 | ▼-11.250 |
| Price To Earnings Diluted Growth Ratio | 7.779 | ▲9.615 | ▲6.625 |
| Price To Book Ratio | 2.802 | ▼-0.419 | ▼-1.467 |
| Price To Sales Ratio | 1.416 | ▼-0.134 | ▼-0.321 |
| Price To Free Cash Flow Ratio | 33.438 | ▲14.716 | ▼-10.251 |
| Price To Operating Cash Flow Ratio | 20.129 | ▲5.732 | ▼-6.567 |
| Debt To Assets Ratio | 0.281 | ▼-0.024 | ▼-0.073 |
| Debt To Equity Ratio | 0.617 | ▼-0.098 | ▼-0.403 |
| Debt To Capital Ratio | 0.381 | ▼-0.035 | ▼-0.108 |
| Long Term Debt To Capital Ratio | 0.293 | ▼-0.041 | ▼-0.122 |
| Financial Leverage Ratio | 2.196 | ▼-0.147 | ▼-0.604 |
| Working Capital Turnover Ratio | 4.431 | ▲0.463 | ▼-0.112 |
| Operating Cash Flow Ratio | 0.349 | ▼-0.229 | ▼-0.021 |
| Operating Cash Flow Sales Ratio | 0.070 | ▼-0.037 | ▼-0.001 |
| Free Cash Flow Operating Cash Flow Ratio | 0.602 | ▼-0.167 | ▼-0.031 |
| Debt Service Coverage Ratio | 5.260 | ▲0.452 | ▲0.377 |
| Interest Coverage Ratio | 4.776 | ▲0.042 | ▲0.353 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | 0.226 | ▼-0.087 | ▲0.043 |
| Capital Expenditure Coverage Ratio | 2.512 | ▼-1.816 | ▼-0.353 |
| Dividend Paid And Capex Coverage Ratio | 2.230 | ▼-1.554 | ▼-0.261 |
| Dividend Payout Ratio | 0.063 | ▲0.003 | ▼-0.009 |
| Enterprise Value Multiple | 12.468 | ▼-0.765 | ▼-3.436 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $745.4M | $811.8M | $824.4M | $939.2M | $1.03B | |
| Enterprise value | $886.7M | $972.8M | $1.02B | $1.15B | $1.26B | |
| EV / Sales | 1.68x | 1.86x | 2.01x | 2.34x | 2.68x | |
| EV / Op. cash flow | 23.95x | 17.25x | 41.34x | 45.93x | 34.42x | |
| EV / Free cash flow | 39.78x | 22.43x | 72.11x | 77.76x | 54.65x | |
| EV / EBITDA | 12.47x | 13.23x | 14.55x | 19.53x | 19.74x | |
| Net debt / EBITDA | 1.99x | 2.19x | 2.84x | 3.53x | 3.65x | |
| Current ratio | 2.02x | 2.32x | 2.53x | 2.05x | 2.08x | |
| Income quality | 1.22x | 1.75x | 0.67x | 1.27x | 1.81x | |
| Graham number | $9 | $9 | $9 | $6 | $6 | |
| Graham net-net | -$4 | -$4 | -$5 | -$6 | -$7 | |
| Tax burden | 64.6% | 68.0% | 89.0% | 64.9% | 54.6% | |
| Interest burden | 81.3% | 78.9% | 75.4% | 72.1% | 79.8% | |
| Working capital | $108.7M | $129.0M | $135.0M | $108.6M | $98.3M | |
| Invested capital | $375.4M | $388.4M | $394.9M | $372.9M | $378.2M | |
| Return on assets | 5.1% | 5.3% | 6.3% | 3.4% | 3.4% | |
| Operating ROA | 8.6% | 10.0% | 9.4% | 7.2% | 7.9% | |
| Return on tangible assets | 6.3% | 6.5% | 7.6% | 4.1% | 4.2% | |
| Return on equity | 11.2% | 12.5% | 16.3% | 10.6% | 12.6% | |
| Return on invested capital | 6.8% | 8.1% | 9.7% | 5.6% | 5.0% | |
| Return on capital employed | 10.6% | 11.9% | 11.0% | 8.7% | 9.2% | |
| Earnings yield | 4.0% | 3.9% | 4.4% | 2.1% | 1.9% | |
| Free cash flow yield | 3.0% | 5.3% | 1.7% | 1.6% | 2.2% | |
| Capex / Op. cash flow | 39.8% | 23.1% | 42.7% | 40.9% | 37.0% | |
| Capex / Depreciation | 100.6% | 87.1% | 67.0% | 59.5% | 73.1% | |
| Capex / Sales | 2.8% | 2.5% | 2.1% | 2.1% | 2.9% | |
| SG&A / Sales | 8.4% | 7.4% | 7.6% | 7.8% | 9.4% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 1.4% | 0.7% | 2.7% | 1.6% | 4.1% | |
| Intangibles / Total assets | 19.3% | 17.9% | 18.1% | 18.5% | 18.5% | |
| Days sales outstanding | 84d | 89d | 88d | 86d | 83d | |
| Days payables outstanding | 31d | 29d | 29d | 41d | 28d | |
| Operating cycle | 130d | 139d | 151d | 139d | 126d | |
| Cash conversion cycle | 98d | 110d | 122d | 99d | 98d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-10-01 CORE LABORATORIES ANNOUNCES TIMING OF THIRD QUARTER 2026 EARNINGS RELEASE AND CONFERENCE CALL HOUSTON, Oct. 1, 2026 /PRNewswire/ -- Core Laboratories (NYSE: "CLB") will host its third quarter 2026 conference call for investors and analysts at 7:30 a.m. CDT / 8:30 a.m.
- 2026-09-22 CLB Declines 35% in the Past Six Months: How to Play the Stock? Core Laboratories'' 35.1% six-month slide contrasts with stronger Production Enhancement trends and offshore recovery potential amid geopolitical risks.
- 2026-09-17 Top 3 Energy Stocks You''ll Regret Missing In September The most oversold stocks in the energy sector presents an opportunity to buy into undervalued companies.
- 2026-09-01 3 Oilfield Services Stocks Poised to Gain Despite Industry Challenges Strict capital discipline by upstream energy companies is acting as a dampener, making the outlook for the Zacks Oil and Gas-Field Services industry gloomy. FTI, OII and CLB are expected to survive the industry woes.
- 2026-08-30 BlackRock Inc. Makes New Investment in Core Laboratories Inc. $CLB BlackRock Inc. acquired a new stake in Core Laboratories Inc. (NYSE: CLB) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 7,460,118 shares of the oil and gas company''s stock, valued at approximately $86,910,000. BlackRock Inc. owned 16.26% of Core Laboratories
- 2026-08-28 Core Laboratories (CLB) Up 18.7% Since Last Earnings Report: Can It Continue? Core Laboratories (CLB) reported earnings 30 days ago. What''s next for the stock?
- 2026-08-22 Advisors Capital Management LLC Makes New $2.77 Million Investment in Core Laboratories Inc. $CLB Advisors Capital Management LLC purchased a new stake in Core Laboratories Inc. (NYSE: CLB) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 237,398 shares of the oil and gas company''s stock, valued at approximately $2,766,000. Advisors Capital Management LLC owned 0.52% of Core
- 2026-08-20 John Rogers Buys Core Laboratories Inc (CLB) -- Shares Look 28% Undervalued on GF Value On June 30, 2026, John Rogers (Trades, Portfolio), founder of Ariel Investment, LLC, increased the firm''s stake in Core Laboratories Inc (NYSE: CLB) by 904,557 s
- 2026-08-11 DTI or CLB: Which Is the Better Value Stock Right Now? Investors looking for stocks in the Oil and Gas - Field Services sector might want to consider either Drilling Tools International Corp. (DTI) or Core Laboratories (CLB). But which of these two stocks is more attractive to value investors?
- 2026-07-31 Is CLB Stock Attractive After Its Sharp Selloff and Mixed Q2 Results? Core Laboratories stock looks cheaper after a 47.1% six-month selloff, but falling earnings and geopolitical pressure keep the near-term case cautious.